CRISPR Therapeutics
CRSP
CRISPR Therapeutics (CRSP) news
Recent news
First pricing secondary offering of stock at $22.20/shr
A company has announced its first pricing secondary offering of stock at $22.20 per share, marking a significant step in its capital-raising strategy. Secondary offerings typically occur after an initial public offering (IPO) and can either be non-dilutive, where existing shareholders sell their…
AInvest Wire · Aug 11, 2026ImportantCRISPR Therapeutics rises 7.2%, Editas Medicine up 8.3% as FDA clears way for faster personalized gene editing treatments
AInvest Wire · Oct 31, 2025Crispr Therapeutics' stock soars 10% as FDA-panel meeting raises hopes sickle-cell-disease drug will be approved
AInvest Wire · Nov 1, 2023CRISPR Therapeutics climbs 18% premarket after reporting completion of FDA advisory committee meeting for Exagamglogene autotemcel (EXA-cel) for severe sickle cell disease
AInvest Wire · Nov 1, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.